Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saccharomyces boulardii in Children With Autism Spectrum Disorder
NCT06568588Phase 2Active, not recruiting
- Sponsor
- Universidad San Francisco de Quito
- Start
- Jan 2024
- Primary completion
- Aug 2026
- Modality
- Microbiome Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of saccharomyces boulardii in Autism Spectrum Disorder (ASD), sponsored by Universidad San Francisco de Quito. Started Jan 2024; status: active, not recruiting.
02
Drugs
saccharomyces boulardii
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT06568588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06568588.